Department of Laboratory, Shenzhen Blood Centre, Shenzhen, China.
Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Transfus Med. 2023 Feb;33(1):81-89. doi: 10.1111/tme.12903. Epub 2022 Aug 16.
In China, the vaccinated blood donors have rapidly increased by recent years, which may impact blood safety. The true prevalence of HBV between vaccinated blood donors and non-vaccinated blood donors should be explored.
The samples of blood donors were collected and detected for serologic markers of HBV in the Shenzhen Blood Centre (SZBC). The discrepant results were tested with commercial electrochemiluminescence immunoassay (ELCI) for HBsAg, anti-HBs, HBeAg, Anti-HBe and Anti-HBc, alternative MPX ID NAT, nested PCR, and a quantitative real-time polymerase chain reaction (qPCR) assay for HBV DNA. The serological and molecular characteristics of HBV infected blood donors were analysed, and the effects on blood safety for donors born before and after the implementation of universal HBV vaccination were compared.
Out of 242 presumed HBV infected donors from 26 318 donations, 131 (0.49%, [95% CI, 0.43-0.59]) chronic HBV infections (CHB, HBsAg detected with or without DNA), 58 (0.22%, [95% CI, 0.17-0.28]) occult hepatitis B infections (OBI, HBsAg not detected, assume anti-HBc positive and/or anti-HBs with HBV DNA) and 3 (0.011%, [95% CI, 0.0023-0.033]) window period (WP) infections were confirmed respectively. There were 28 CHBs (0.44%), 7 OBIs (0.11%) and 1 WP (0.016%) from vaccinated blood donor and 103 CHBs (0.52%), 51 OBIs (0.26%) and 2 WPs (0.01%) from non-vaccinated blood donor. The HBV+ (CHBs, OBIs and WPs) rate (0.56%) in vaccinated donors was lower than in non-vaccinated donors (0.78%, p < 0.05). The HBsAg titers of vaccinated infected blood donors (Median: 128.8 IU/ml) were much higher than non-vaccinated infected blood donors (58.4 IU/ml). The OBI yield rates in the vaccinated blood donors was significantly lower than the non-vaccinated blood donors (p < 0.05). There 102/124 (82.3%) samples were genotype B, 22/124 (17.7%) were genotype C respectively. There was no significant difference in the distribution of genotype between non-vaccinated blood donors (B/C, 86/17) and vaccinated blood donors (B/C, 23/6; p > 0.05). High frequency of vaccine escape mutations M133L (32.4%) and E164G in S region of genotype B strains and substitution L175S (40.9%) related to vaccine escape in S region of genotype C strains were identified.
The universal HBV vaccination program markedly reduces the risk of HBV infection in blood donors, and provides a significant guarantee for the safety of blood transfusion. Several important mutations detected related vaccine escape and notable mutations needed further investigated.
近年来,中国的已接种疫苗献血者数量迅速增加,这可能会影响血液安全。因此,需要探索已接种疫苗和未接种疫苗献血者之间 HBV 的真实流行率。
在深圳血液中心(SZBC)采集献血者样本并检测 HBV 的血清学标志物。对于 HBsAg、抗-HBs、HBeAg、抗-HBe 和抗-HBc 的酶联免疫吸附试验(ELISA)检测结果不一致的样本,采用商业电化学发光免疫分析(ECLI)、替代 MPX ID NAT、巢式 PCR 和实时荧光定量聚合酶链反应(qPCR)进行 HBV DNA 检测。分析 HBV 感染献血者的血清学和分子特征,并比较实施普遍 HBV 疫苗接种前后对献血者血液安全的影响。
在 26318 份献血中,242 份被认为是 HBV 感染的献血者,其中 131 例(0.49%[95%CI,0.43-0.59%])为慢性 HBV 感染(CHB,HBsAg 检测阳性,无论是否存在 DNA),58 例(0.22%[95%CI,0.17-0.28%])为隐匿性乙型肝炎感染(OBI,HBsAg 未检测到,假设抗-HBc 阳性和/或抗-HBs 阳性,存在 HBV DNA),3 例(0.011%[95%CI,0.0023-0.033%])为窗口期感染(WP)。其中,28 例 CHB(0.44%)、7 例 OBI(0.11%)和 1 例 WP(0.016%)来自已接种疫苗的献血者,而 103 例 CHB(0.52%)、51 例 OBI(0.26%)和 2 例 WP(0.01%)来自未接种疫苗的献血者。接种疫苗的献血者中 HBV+(CHB、OBI 和 WP)的比例(0.56%)低于未接种疫苗的献血者(0.78%,p<0.05)。接种感染献血者的 HBsAg 滴度(中位数:128.8 IU/ml)明显高于未接种感染献血者(58.4 IU/ml)。接种疫苗的献血者中 OBI 的检出率明显低于未接种疫苗的献血者(p<0.05)。124 份样本中,102 份(82.3%)为基因型 B,22 份(17.7%)为基因型 C。未接种疫苗的献血者(B/C,86/17)和接种疫苗的献血者(B/C,23/6)之间的基因型分布无显著差异(p>0.05)。在 B 型株的 S 区发现了 M133L(32.4%)和 E164G 等高频疫苗逃逸突变,在 C 型株的 S 区发现了与疫苗逃逸相关的 L175S(40.9%)取代。
普遍的 HBV 疫苗接种计划显著降低了献血者 HBV 感染的风险,为输血安全提供了重要保障。检测到的几种重要的与疫苗逃逸相关的突变和显著突变需要进一步研究。